Company intelligence / Profile preview

OncoDiag

Ownership: Private
Development stage: Commercial

Overview

OncoDiag has developed Urodiag, a CE-IVD marked urine-based diagnostic test for the surveillance of bladder cancer. The company’s pipeline also includes Colodiag, a non-invasive diagnostic in development for colorectal cancer screening[2].

Therapeutic areas: Oncology
Modalities: Diagnostic test
Industry: Molecular Diagnostics

Drug pipeline

3 assets

Urodiag

Commercial

Indications: Bladder cancer

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on OncoDiag.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncoDiag.

Explore the full profile